Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA

Article Oncology

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

Debyani Chakravarty et al.

Summary: ASCO's provisional clinical opinion provides guidance on the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors. Genomic sequencing should be performed in a certified laboratory for patients with specific genomic alterations that have regulatory approval as biomarkers. Multigene panel-based assays can be used to identify additional treatment targets. Site-agnostic approvals for cancers with high tumor mutation burden, mismatch repair deficiency, or neurotrophic tyrosine receptor kinase (NTRK) fusions justify genomic testing for all solid tumors. The functional impact of targeted alterations and the expected efficacy of genomic biomarker-linked options should be considered for treatment planning.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network

Nicholas J. Robert et al.

Summary: The MYLUNG consortium study examined real-world biomarker testing rates and turnaround times within a community cancer network, finding that while most patients received at least one biomarker test, less than 50% received all five tests.

LUNG CANCER (2022)

Add to Collection

Article Oncology

Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States

Debora S. Bruno et al.

Summary: This study analyzed the racial differences in biomarker testing and clinical trial participation among Black and White patients using a real-world database. The results showed significant disparities in NGS-based testing rates between Black and White patients with NSCLC and CRC. Black patients were less likely to participate in clinical trials. Interventions are needed to promote access to comprehensive testing for patients with advanced/metastatic tumors.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination

Daniel M. Sheinson et al.

Summary: The study examined the association between Medicare NCD and NGS use by insurance types and race/ethnicity, finding that changes in NGS testing trends post-NCD were similar between Medicare and commercially insured patients, while slower among those in assistance programs. There were no statistically significant changes in NGS use trends by racial/ethnic groups within Medicare beneficiaries alone or across all insurance types.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Oncology

Non-Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment

Dara L. Aisner et al.

Summary: The 2021 updates to the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) emphasize the importance of biomarker testing for newly diagnosed advanced lung cancer patients and recommend targeted first-line therapies based on genetic alterations. Additionally, adjuvant treatment with osimertinib for resected early-stage EGFR-mutated NSCLC is highlighted. New recommendations include targeted agents for ALK rearrangements, RET alterations, MET exon 14 skipping mutations in advanced NSCLC, as well as immunotherapy agents for advanced NSCLC without a driver oncogene.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology